Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 18

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 18
---
6, 2079.

#### Equity
Total Equity as of December 31, 2024 was JPY 7,419.2 billion ( JPY +145.2 billion). The increase of Other Components of Equity ( JPY +192.2 billion) was mainly due to fluctuation in currency translation adjustments reflecting the depreciation of the Japanese yen. This increase was partially offset by the decrease in Retained Earnings ( JPY -100.3 billion ) due to the decrease of JPY 303.2 billion related to dividend payments offset by the increase of JPY 211.2 billion from Net Profit for the Period.

<div align='center'>10</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

(ii) Consolidated Cash Flows

|                                                                   |     | Billion JPY |        |     |           |        |     |        |        |
|                                                                   |     | FY2023 Q3   |        |     | FY2024 Q3 |        |     | Change |        |
| Net cash from operating activities                                |     |             |  437.8 |     |           |  835.0 |     |        |  397.3 |
| Net cash used in investing activities                             |     |             | -402.4 |     |           | -347.4 |     |        |   55.0 |
| Net cash used in financing activities                             |     |             | -296.2 |     |           | -449.6 |     |        | -153.4 |
| Net increase (decrease) in cash and cash equivalents              |     |             | -260.8 |     |           |   38.0 |     |        |  298.8 |
| Cash and cash equivalents at the beginning of the year            |     |             |  533.5 |     |           |  457.8 |     |        |  -75.7 |
| Effects of exchange rate changes on cash and cash equivalents     |     |             |   15.6 |     |           |   -1.7 |     |        |  -17.3 |
| Cash and cash equivalents at the end of the period                
 (Condensed interim consolidated statements of financial position) |     |             |  288.4